DENTSPLY SIRONA -- The Essentials

By Chris Stiles • Friday, June 16 15:04 • Permanent Link

DENTSPLY SIRONA logged a 2.6% change during today's afternoon session, and is now trading at a price of $39.4 per share. The S&P 500 index moved -0.0%. XRAY's trading volume is 2,790,229 compared to the stock's average volume of 1,798,736.

DENTSPLY SIRONA trades -11.86% away from its average analyst target price of $44.7 per share. The 10 analysts following the stock have set target prices ranging from $40.0 to $51.0, and on average have given DENTSPLY SIRONA a rating of hold.

If you are considering an investment in XRAY, you'll want to know the following:

DENTSPLY SIRONA has moved 8.7% over the last year, and the S&P 500 logged a change of 20.4%
Based on its trailing earnings per share of -4.82, DENTSPLY SIRONA has a trailing 12 month Price to Earnings (P/E) ratio of -8.2 while the S&P 500 average is 15.97
XRAY has a forward P/E ratio of 17.3 based on its forward 12 month price to earnings (EPS) of $2.28 per share
The company has a price to earnings growth (PEG) ratio of 5.1 — a number near or below 1 signifying that DENTSPLY SIRONA is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.3 compared to its sector average of 4.16
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide.
Based in Charlotte, the company has 15,000 full time employees and a market cap of $8.37 Billion. DENTSPLY SIRONA currently returns an annual dividend yield of 1.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.